Security Snapshot

AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) Institutional Ownership

CUSIP: 037326105

13F Institutional Holders and Ownership History from Q1 2022 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

37

Shares (Excl. Options)

8,664,575

Price

$1.14

Type / Class
Equity / Common Stock, par value $0.00001 per share
Symbol
ANTX on Nasdaq
Shares outstanding
37,347,828
Price per share
$5.44
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
8,664,575
Total reported value
$9,877,677
% of total 13F portfolios
0%
Share change
+388,258
Value change
+$437,838
Number of holders
37
Price from insider filings
$5.44
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ANTX - AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 037326105.
  • 37 institutions reported positions in Q4 2025.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 35 to 37 between Q3 2025 and Q4 2025.
  • Reported value moved from $10,511,010 to $9,877,677.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 037326105?
CUSIP 037326105 identifies ANTX - AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 9.9% $4,880,614 3,697,435 Commodore Capital LP 09 Mar 2026
Almitas Capital LLC 5.4% +4% $3,927,216 +$2,041,830 2,975,164 +108% Almitas Capital LLC 31 Dec 2025
Vivo Opportunity Fund Holdings, L.P. 8% $3,780,937 2,864,346 Vivo Opportunity Fund Holdings, L.P. 10 Mar 2026
Coastlands Capital Partners LP 9.3% $3,632,511 2,815,900 Coastlands Capital LP 28 May 2025
Adjuvant Global Health Technology Fund, L.P. 7.9% $3,061,815 2,373,500 Adjuvant Capital GP, L.P. 31 Dec 2024
INTEGRATED CORE STRATEGIES (US) LLC 6.3% $2,952,975 2,237,102 Millennium Management LLC 06 Mar 2026
Easom Eric 7.9% +28% $2,946,245 +$447,311 2,232,004 +18% Eric Easom 31 Dec 2025
Brii Biosciences Ltd 3.1% $1,196,089 927,201 Brii Biosciences Limited 31 Dec 2024
BML Investment Partners, L.P. 1.4% -85% $551,387 -$3,599,088 427,432 -87% BML Investment Partners, L.P. 17 Jun 2025

As of 31 Dec 2025, 37 institutional investors reported holding 8,664,575 shares of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX). This represents 23% of the company’s total 37,347,828 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) together control 23% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Almitas Capital LLC 4% 1,479,129 +3.6% 0.37% $1,686,207
VANGUARD GROUP INC 2.9% 1,080,070 0% 0% $1,231,280
Pfizer Inc 1.9% 715,295 0% 0.34% $815,436
Stonepine Capital Management, LLC 1.7% 627,668 +11% 0.57% $715,542
Peapod Lane Capital LLC 1.6% 593,396 +0.71% 0.58% $676,471
BANK OF NOVA SCOTIA 1.2% 459,194 0% 0% $523,481
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 1.2% 431,760 -5.4% 0.03% $492,206
BANK OF MONTREAL /CAN/ 1.1% 422,077 0% 0% $481,168
BANK OF AMERICA CORP /DE/ 1% 385,312 +0% 0% $439,256
RENAISSANCE TECHNOLOGIES LLC 0.91% 338,600 -12% 0% $386,004
BlackRock, Inc. 0.87% 323,335 +0.76% 0% $368,602
TWO SIGMA ADVISERS, LP 0.71% 264,900 -1.1% 0% $301,986
GEODE CAPITAL MANAGEMENT, LLC 0.67% 251,875 +1% 0% $287,199
MORGAN STANLEY 0.62% 229,770 +20% 0% $261,938
TWO SIGMA INVESTMENTS, LP 0.48% 178,518 -20% 0% $203,511
Woodline Partners LP 0.39% 145,971 0% $166,407
CITADEL ADVISORS LLC 0.31% 115,536 +402% 0% $131,711
MILLENNIUM MANAGEMENT LLC 0.26% 95,683 0% $109,079
STATE STREET CORP 0.23% 87,002 0% 0% $99,182
Rangeley Capital, LLC 0.17% 65,000 0% 0.06% $74,100
Squarepoint Ops LLC 0.16% 61,612 -4.1% 0% $70,238
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.16% 59,900 0% 0% $68,286
UBS Group AG 0.15% 56,668 -0.05% 0% $64,601
NORTHERN TRUST CORP 0.12% 43,196 0% 0% $49,243
CAPTRUST FINANCIAL ADVISORS 0.11% 40,000 0% 0% $45,600

Institutional Holders of AN2 Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ANTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 8,664,575 $9,877,677 +$437,838 $1.14 37
2025 Q3 8,276,317 $10,511,010 +$7,414 $1.27 35
2025 Q2 8,284,557 $8,781,263 -$8,600,258 $1.06 36
2025 Q1 14,340,830 $19,503,615 -$264,699 $1.36 37
2024 Q4 14,528,930 $20,050,012 +$893,482 $1.38 37
2024 Q3 13,513,224 $14,458,906 -$16,315,888 $1.07 31
2024 Q2 19,415,909 $41,730,123 -$1,462,207 $2.15 45
2024 Q1 18,733,564 $60,875,021 -$18,042,573 $3.25 54
2023 Q4 20,391,503 $417,920,110 +$9,592,150 $20.49 51
2023 Q3 19,931,490 $320,311,244 +$132,978,201 $16.08 37
2023 Q2 11,741,328 $99,891,167 +$18,097,549 $8.50 30
2023 Q1 9,600,229 $94,752,948 -$1,565,644 $9.87 37
2022 Q4 9,762,608 $93,037,767 -$3,679,262 $9.53 35
2022 Q3 9,496,676 $165,051,000 +$1,938,968 $17.38 35
2022 Q2 9,386,370 $72,410,000 +$2,199,519 $7.75 32
2022 Q1 8,952,537 $134,111,000 +$134,111,000 $15.07 18

Sponsored